Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00259-025-07467-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of [Ga]Ga-FAPI-04 and [F]FDG PET/CT for detection of bone metastases of lung cancer.
Quant Imaging Med Surg
September 2025
Department of Nuclear Medicine, Institute of Traditional Chinese Medicine of Sichuan Academy of Chinese Medicine Sciences (Sichuan Second Hospital of Traditional Chinese Medicine), Chengdu, China.
Background: Bone metastases of lung cancer typically indicate disease progression and poor prognosis. Early and accurate detection is crucial for staging, treatment planning, and prognostic evaluation. This study aimed to compare the diagnostic value of gallium 68-labeled fibroblast-activation protein inhibitor-04 ([Ga]Ga-FAPI-04) and fluorine 18-labeled fluorodeoxyglucose ([F]FDG) positron-emission tomography/computed tomography (PET/CT) imaging in detecting bone metastases in lung cancer.
View Article and Find Full Text PDFSynthesis, Radiolabeling, and Evaluation of a Dimeric Fibroblast Activation Protein Inhibitor with a Triazine Linker.
Mol Pharm
September 2025
Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea.
Dimeric fibroblast activation protein inhibitor (FAPI) radioligands are promising candidates for theranostic applications because of their enhanced tumor uptake and prolonged retention compared to monomeric radioligands. Several linker strategies have been investigated to connect two FAPI motifs and a radiometal chelator in a dimer design. In this study, we report the development of a novel dimeric FAPI radioligand, [Ga]Ga-, which utilizes a triazine core as a trifunctional linker.
View Article and Find Full Text PDFThe superiority of [Ga]Ga-FAPI PET/CT over MRI and [F]FDG PET/CT in delineating a rare case of pituitary fibrosarcoma.
Eur J Nucl Med Mol Imaging
July 2025
Department of Nuclear Medicine, State Key Laboratory of Complex, Severe, and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking
[18F]FDG PET/CT is Superior to [68Ga]Ga-FAPI PET/CT for Lesion Detection in Extranodal NK/T-cell Lymphoma, Nasal Type.
Clin Nucl Med
July 2025
Department of Nuclear Medicine, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu, Sichuan, China.
Background: This study aimed to assess the feasibility of [68Ga]Ga-FAPI PET/CT for detecting lesions in extranodal NK/T-cell lymphoma, nasal type (ENKTL-NT), and to compare its diagnostic performance with [18F]FDG PET/CT in clinical practice.
Patients And Methods: Between December 2022 and December 2023, 19 patients with pathologically confirmed ENKTL-NT at West China Hospital underwent baseline [68Ga]Ga-FAPI and [18F]FDG PET/CT. Lesions were documented by each modality, and detection rates compared at both patient and lesion levels.
Same-day dual-tracer PET/CT imaging with [ Ga]Ga-FAPI-04 following [F]FDG finds answers in patients presenting with negative or equivocal [F]FDG.
Ann Nucl Med
July 2025
Department of Nuclear Medicine, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
Objective: Gallium-68-labelled fibroblast activation protein inhibitor ([ Ga]Ga-FAPI) is a tumour-stromal imaging agent showing complementary value alongside fluorine-18 fluorodeoxyglucose ([F]FDG) in cancer imaging. This study investigated the feasibility of a same-day dual-tracer positron emission tomography/computed tomography (PET/CT) protocol with [ Ga]Ga-FAPI-04 following [F]FDG in patients presenting with negative or equivocal [F]FDG.
Methods: Patients with negative or equivocal [F]FDG findings underwent dual-tracer PET/CT (named FDG-mixed FAPI PET/CT, abbreviated to mFAPI PET/CT) on the same day, with [ Ga]Ga-FAPI-04 administered 4.